Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
ABB's shares surged 10% following its annual results, with earnings per share exceeding forecasts. Analysts have raised their price target to CHF 60.30 and project accelerated revenue growth ahead of industry peers.
A revised analyst price target for Grupo Financiero Banorte (BMV:GFNORTE O) is refocusing investor attention on the Mexican banking giant, highlighting how evolving assessments of risk and growth potential can rapidly reshape a stock's narrative.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.
TD Cowen raises Prudential Financial's price target to $113, maintaining a 'Hold' rating, as the insurer grapples with a misconduct scandal at its Japan life insurance unit affecting nearly 500 customers.
Stifel Nicolaus lowered its price target on Altria Group (MO) by $4 to $68, citing higher-than-expected operating costs. Despite near-term headwinds, the firm reaffirmed its Buy rating, pointing to the tobacco giant's resilient dividend profile and long-term earnings guidance.
The asset manager declares a $0.03 per share payout, with its dividend yield sitting below industry average as a rising stock price and robust earnings growth paint a complex picture for income-focused investors.
A sharp supply crunch is driving contract prices for mainstream DRAM memory chips up by as much as 95% quarter-on-quarter in early 2025, according to a revised forecast from market analyst TrendForce.
Truist Securities raised its price target on Fifth Third Bancorp (FITB) following a robust quarterly performance driven by loan growth and fee income, while slightly adjusting its long-term earnings outlook due to acquisition timing and tax considerations.
Wells Fargo updates its long-term valuation for American Electric Power (AEP), raising its price target to $140, as the utility secures a major fuel cell investment and a 20-year power purchase agreement for a new Wyoming facility.
Analyst firm Argus has raised its price target for Sanmina Corporation (SANM) to $200, maintaining a Buy rating following the company's better-than-expected Q1 2026 results and robust positioning in key growth markets.
A wave of subscription increases from Netflix, Disney, Apple, and others is forcing consumers to rethink their streaming budgets, with ad-supported tiers and strategic bundling emerging as key cost-saving strategies.
A strategic report warns that recent tariff hikes could significantly increase clothing costs for American shoppers unless brands rapidly diversify production to a network of partner nations.
Sugar futures tumbled further this week, with New York prices hitting a 2.5-month low and London white sugar sinking to a five-year trough, as analysts warn of swelling global surpluses driven by record harvests in Brazil and India.
Northland Capital has revised its price target for Bitdeer Technologies (BTDR) downward to $25, citing a more conservative valuation approach following the company's latest operational update. The firm, however, reaffirmed its Outperform rating, signaling continued confidence in the blockchain and high-performance computing firm's long-term strategy.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
